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Glycogen storage disease Ia (GSD Ia) is an autosomal
recessive inborn error of carbohydrate metabolism that
is caused by a deficiency of the enzyme glucose-
6-phosphatase, leading to disturbed glycogenolysis and
gluconeogenesis. Patients with GSD Ia are dependent on
supplementary exogenous sources of glucose and suffer
severe fasting hypoglycemia, lactic acidosis, hyperurice-
mia, and hyperlipidemia. The primary objective in treat-
ment is to prevent hypoglycemia either by frequent meals,
consumption of uncooked cornstarch, continuous gastric
drip feeding, or glucose infusion.1 GSD Ia presenting as
neonatal hypoglycemia is uncommon, as most GSD Ia pa-
tients are diagnosed at a median age of 3e6 months.2 Here,
we describe a case of neonatal GSD Ia. The diagnosis was
confirmed by gene analysis.
2. Brief report
A 33-year-old woman gave birth vaginally to a male infant at
38 4/7 weeks gestational age, with a birth weight of 3100 g
and good Apgar scores. Therewas no family history of liver or
metabolic disease. At age 3 days, the infant was admitted to
hospital because of pneumonia. During his hospitalization,
he was found to have hypoglycemia and prominent hepato-
megaly, liver palpable at 4 cm below the right costal margin,
but no splenomegaly. Biochemical tests on Day 7 showed a* Corresponding author. Neonatal Department of Children’s
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aspartate amino transferase 233 IU/L, and fasting hypogly-
cemia 1.8 mM, (neonatal hypoglycemia defined as glucose
<2.6 mM). Biochemical tests on Day 14 showed worsening
transaminase levels with alanine amino transferase 216 U/L,
and aspartate amino transferase 561 IU/L. On Day 16, he was
referred to our hospital for further investigations.
On the day of admission, his physical examination showed
hepatomegaly with liver palpable at 3.5 cm below the right
costal margin and mild wasting of his limbs. His coagulation
function was normal. After admission, he had prefeeding
glucose levels <2.6 mM on four occasions, which quickly
returned to normal after feeding. His fasting blood analyses
revealed hypoglycemia, lactic acidosis, and hyper-
triglyceridemia. On Day 19, before feeding, his glucose level
was1.8mmol/L, and functional tests showed theabsenceof a
glycemic response and an aggravation of lactic acidosis after
injection of glucagon. His thyroid function and insulin/
glucose ratio were normal with glucose level at 1.8 mM. On
Day 20, his urine was tested for galactosemia. Due to the
hypertriglyceridemia, he was fed every 2 hours with a special
formula thatwas galactose-free and containedmediumchain
triglycerides (MCTs), pending urine results. On Day 20, his
blood was sent for genetic testing.
His urine test ruled out galactosemia. His fasting blood
glucose level was maintained within normal range, lactate
and triglycerides levels decreased gradually, and liver
function tests also improved substantially by Day 25
(Table 1). Gene analysis revealed a homozygous mutation in
exon 1 (c.202 G > A, pG68 R, CM980780, PMID:9700613),
which was first reported in 1998.3 His parents refused ge-
netic testing. He was transitioned from MCT formula to
regular formula and the parents were taught how to feed
him andmonitor his glucose before he was discharged home.y Elsevier Taiwan LLC. All rights reserved.
Table 1 Biochemical test results during hospitalization.
Blood glucose
(3.9e6.1 mM)
Alanine amino
transferase
(0e40 IU/L)
Aspartate amino
transferase
(0e40 IU/L)
Triglyceride
(0.56e1.7 mM)
Lactate
(0e4 mM)
Day 16 1.6 175 259 2.41 5.1
Day 18 1.8 161 274 3.68 10.4
Day 21 4.5 85 86 3.08 4.3
Day 25 4.3 68 111 1.98 2.3
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Hypoglycemia is a life-threatening problem in patients
with GSD Ia. More commonly, patients present at around age
3 months with a protruding abdomen due to marked hepato-
megaly.Ourpatientwasdiagnosedduring theneonatalperiod,
and neonatal GSD has only been reported occasionally.4
Unlike long chain triglycerides, MCTs are not incorpo-
rated into chylomicrons, and the released medium-chain
fatty acids enter mitochondria without the carnitine system
that is essential for long-chain fatty acids to pass through
the mitochondrial membrane. Patients with GSD Ia do
not require special formula, although Nagasaka et al5 found
that MCT milk helped lower blood triglyceride levels
and raise HDL cholesterol levels in GSD Ia patients. Before
we ruled out galactosemia in our patient with hyper-
triglyceridemia, we fed a special galactose-free, MCT
formula. After we fed him every 2 hours, his glucose levels
were maintained in the normal range, and the hyper-
triglyceridemia and lactic acidosis gradually improved.
The human glucose-6-phosphatase gene was isolated by
Lei et al,6 and has been localized to chromosome17 at 17q21.
It includes fives exons and codes for a highly hydrophobic
protein of 357 amino acids containing nine transmembrane
helices. More than 85 mutations (Human Gene Mutation
Database; http://www.hgmd.cf.ac.uk) have been identi-
fied.7 The diagnosis in our patient was confirmed by gene
analysis. Hufton and Wharton4 also suggested that in the
neonatal period, any unexplained metabolic acidosis, hy-
poglycemia, hepatomegaly, or hyperlipidemia merits the
consideration of GSD in the differential diagnosis. Complete
sequencing of the GSD Ia genes allows diagnosis in nearly all
patients with evocative clinical and biochemical signs of GSD
Ia,8 thereby eliminating the need for a liver biopsy.
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